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ESKAPE (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae,
Acinetobacter baumanni, Pseudomonas aeruginosa, and Enterobacter species)
pathogens have characteristic multiple-drug resistance and cause an increasing number
of nosocomial infections worldwide. Peptide-based therapeutics to treat ESKAPE
infections might be an alternative to conventional antibiotics. Histatin 5 (Hst 5) is a salivary
cationic histidine-rich peptide produced only in humans and higher primates. It has
high antifungal activity against Candida albicans through an energy-dependent, non-lytic
process; but its bactericidal effects are less known. We found Hst 5 has bactericidal
activity against S. aureus (60–70% killing) and A. baumannii (85–90% killing) in 10
and 100mM sodium phosphate buffer (NaPB), while killing of >99% of P. aeruginosa,
60–80% E. cloacae and 20–60% of E. faecium was found in 10 mM NaPB. Hst 5 killed
60% of biofilm cells of P. aeruginosa, but had reduced activity against biofilms of S. aureus
and A. baumannii. Hst 5 killed 20% of K. pneumonia biofilm cells but not planktonic cells.
Binding and uptake studies using FITC-labeled Hst 5 showed E. faecium and E. cloacae
killing required Hst 5 internalization and was energy dependent, while bactericidal activity
was rapid against P. aeruginosa and A. baumannii suggesting membrane disruption. Hst
5-mediated killing of S. aureus was both non-lytic and energy independent. Additionally,
we found that spermidine conjugated Hst 5 (Hst5-Spd) had improved killing activity
against E. faecium, E. cloacae, and A. baumannii. Hst 5 or its derivative has antibacterial
activity against five out of six ESKAPE pathogens and may be an alternative treatment
for these infections.
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INTRODUCTION
Bacteria causing nosocomial infections are increasingly becoming drug resistant, posing a serious
health concern, especially in the Intensive Care Units (ICUs) and in surgical wards. A recent report
estimated a total of 722,000 of such drug-resistant infections, with an astonishing 75,000 resulting
in deaths (Magill et al., 2014). A group of bacterial pathogens including Enterococcus faecium,
Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumanii, Pseudomonas aeruginosa,
and Enterobacter species (referred to as ESKAPE pathogens) have been of particular concern in
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this regard (Rice, 2010). Two-thirds of all healthcare-associated
infections are ESKAPE related (Boucher et al., 2009), and many
of these bacteria use multiple drug resistance mechanisms to
“eskape” killing by both conventional and some newer generation
antibiotics (Rice, 2008).
Most nosocomial infections result from an exogenous
inoculum including the hospital environment and medical
personnel, resulting in colonization of ESKAPE pathogens within
various patient niches. E. faecium, K. pneumoniae, P. aeruginosa,
and Enterobacter species are common residents of mucosal
surfaces such as the oral cavity and the gastrointestinal tract
(Keller et al., 1998; Podschun and Ullmann, 1998; Rice, 2010;
Vu and Carvalho, 2011). S. aureus is a skin commensal and A.
baumanni has been known to have comparatively long survival
rates on epithelial surfaces (e.g., skin; Houang et al., 1998; Coates
et al., 2014). Also, P. aeruginosa and K. pneumonia were detected
in 50 and 31%, respectively, of HIV-positive patients’ salivas in
hospital settings (Lopes et al., 2015). Thus, colonization of the
oral cavity with K. pneumoniae, P. aeruginosa, and Enterobacter
species can serve as a potential inoculum source for pneumonia
(Sands et al., 2016). Furthermore, Candida albicans, an oral
commensal fungus also present in the oral cavity, can contribute
to a more robust P. aeruginosa lung infection if the two are
present together (Lindsay and Hogan, 2014).
Salivary innate immunity is the first line of defense against
transient and pathobionts in the oral cavity (Salvatori et al., 2016).
This is illustrated by the example of salivary Histatin 5 (Hst 5),
a cationic protein that has strong fungicidal activity against C.
albicans (Puri and Edgerton, 2014). Changes in the levels of Hst
5 associated with immunodeficiency may increase susceptibility
to oral candidiasis caused by C. albicans (Khan et al., 2013).
However, Hst 5 was shown to be largely ineffective against
oral commensal bacteria as well as cariogenic or periodontal
pathogens (Devine and Hancock, 2002; Groenink et al., 2003;
Dale and Fredericks, 2005).
However, antimicrobial activity of Hst 5 against the
ESKAPE pathogens has never been examined. Hst 5-mediated
candidacidal activity is an energy-dependent, non-lytic process,
where multiple intracellular targets are affected after Hst 5 has
been transported to the cytosol in an energy dependent manner
(Puri and Edgerton, 2014). Given the fact that most ESKAPE
pathogens are not present in large numbers in the oral cavity of
healthy humans, and do not cause any known oral diseases, we
hypothesized that salivary Hst 5 may play a substantial role in
keeping at least some of the ESKAPE pathogens in check within
the oral environment. Here we show for the first time that Hst
5 demonstrates killing activity against all ESKAPE pathogens
except K. pneumoniae. Killing against some ESKAPE pathogens
was lytic in nature; however, as for C. albicans, more than one
mechanism of killing seems to be involved in Hst 5 activity
against ESKAPE bacteria.
MATERIALS AND METHODS
Strains, Culture Conditions, and Peptides
All ESKAPE strains used in this study are clinical isolates and
are listed in Table 1. These isolates were collected over the past
TABLE 1 | ESKAPE strains used in this study.
Species Strain # Gram
staining
Source*
Enterococcus faecium 94-346-1139 + Buffalo, NY
Staphylococcus aureus 299-0432 + Buffalo, NY
Staphylococcus aureus (MRSA) 94-292-1348 + Buffalo, NY
Klebsiella pneumoniae Montreal #33 - Montreal, Canada
Acinetobacter baumannii AB307-0294 - Buffalo, NY (Adams
et al., 2008)
Acinetobacter baumannii HUMC1 - (Luo et al., 2012)
Pseudomonas aeruginosa 94-323-0635 - Buffalo, NY
Pseudomonas aeruginosa PAO1 - Sutton lab, Buffalo, NY
Enterobacter cloacae 94-293-0624 - Buffalo, NY
*Isolates from the University at Buffalo were collected over the past 20 years directly from
the clinical microbiology laboratory, which performed strain identification by approved
laboratory methodology.
20 years directly from the clinical microbiology laboratory at
the University at Buffalo, which performed strain identification
by approved laboratory methodology. Isolates from de-identified
plates were frozen and stored at −80◦C. Enterococcus faecium
and Staphylococcus aureus were grown in Trypticase soy broth
(Sigma-Aldrich; TSB) or TSB agar. All other strains were cultured
in Luria-Bertani (LB; BD Biosciences) broth or on LB agar.
The incubation temperature for all strains was 37◦C. Histatin 5
(Hst 5), FITC-labeled Hst 5 (F-Hst 5), and spermidine conjugated
Histatin 5 (Hst 5-Spd) were synthesized by Genemed Synthesis
Inc. (San Antonio, Texas). Spermidine was purchased from
Sigma-Aldrich.
Bactericidal Assay
Bactericidal assays were performed by microdilution plate
method as described for candidacidal assays (Jang et al., 2010),
with some modifications. Briefly, a single colony of each strain
was inoculated into 10 mL of media and grown for 16 h at 37◦C,
cultures were diluted to an OD600 = 0.1 in fresh media and
incubated with shaking at 37◦C to mid-log phase (OD600 ≈ 1.0).
Cultures were spun down at 1800× g for 3 min and washed three
times with 10mM sodium phosphate buffer (pH 7.4; NaPB). Cells
were re-suspended (107 cells/mL) in 200 µL NaPB (control) or
in NaPB containing peptides (30 µM); then incubated at 37◦C
(except for S. aureus that was incubated at room temperature
for optimal growth). Aliquots were removed after 1 min, 1 h
and 5 h incubation, then were serially diluted with phosphate
buffered saline (PBS; 137 mM NaCl, 10 mM sodium phosphate,
2.7 mM KCl, pH of 7.4); plated and incubated for 24 h at 37◦C
to visualize surviving CFUs. Assays were performed in triplicate.
Percentage killing was calculated as [1 − number of colonies
from peptide-treated cells/mean number of colonies from control
cells]× 100%. Bactericidal assays were also performed in 100mM
NaPB and PBS.
Live Cell Imaging of F-Hst 5 and PI Uptake
by Time-Lapse Confocal Microscopy
Confocal microscopy was performed using live cells of six
ESKAPE strains attached to chambered borosilicate coverglass
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(Lab-Tek #155411, 8 chamber). Cells in mid-log phase were
collected and washed three times and re-suspended in 10 mM
NaPB. Cells (2 × 107 in 200 µL NaPB) were added to each
well, allowed to settle for 15 min, then propidium iodide (PI; 2
µg/mL; Sigma) and F-Hst 5 (30 µM) were added. Time-lapse
confocal images were recorded immediately after addition of
peptide and PI. Confocal images were acquired with a Zeiss
LSM510 Meta Confocal Microscope (Carl Zeiss, Germany) using
a Plan Apochromat 63X/1.4 Oil Immersion objective. For E.
faecium, S. aureus, K. pneumoniae, and E. cloacae, images were
collected every 10 min; and for A. baumannii and P. aeruginosa
every 2 min. In order to detect F-Hst 5 and PI simultaneously,
the 488 nm line of the argon ion laser and a 561 nm DPSS
laser were directed over an HFT UV/488/561 beam splitter, and
fluorescence was detected using a Mirror or NFT 565 beam
splitter in combination with a BP 500–550 filter for F-Hst 5 and
an LP 575 or BP 650–710 filter for PI detection. ImageJ software
was used for image acquisition and analysis.
Biofilm Killing Assays
To evaluate killing of bacterial biofilms by Hst 5, cells were
inoculated at 1 × 107 cells/ml into 96 well plates and grown
overnight at 37◦C and 90 RPM for 12 h to form biofilms. After
12 h, spent media was replaced with fresh media, and biofilms
were grown for another 4 h in the same conditions. Media
was removed and biofilms were incubated with 30 µM Hst 5
suspended in 10 µM NaPB with 10 µM propidium iodide (PI)
for 1 h at 37◦C, except for S. aureus which was incubated at RT.
After 1 h, biofilms were gently scraped to remove them from
each well, diluted, and placed on microscope slides for image
acquisition using a Zeiss Axioobserver.Z1 inverted fluorescent
microscope, and an Axiocam 503M camera. Percent killing
was calculated as the number of PI positive cells divided by
the total number of cells from at least 25 fields from two
independent wells.
Hst 5 Killing Activity Determination in
Energy Deprived Cells
Overnight cultures of E. faecium, S. aureus, A. baumannii, and E.
cloacae were diluted and pre-incubated with 10% of media with
or without 10 mM NaN3 at 37
◦C. P. aeruginosa cells were pre-
incubated in 10 mM NaPB with 10 mM NaN3 at 37
◦C due to
altered cell viability in the presence of 10% media with NaN3.
After 3 h incubation, cells were collected by centrifugation and
washed two times with NaPB; then cells were used for Hst 5
bactericidal assay in NaPB as described above.
Susceptibility Assay
Minimum inhibitory concentration (MIC) was determined by
broth microdilution method based on the guide of Clinical and
Laboratory Standards Institute (Clinical Laboratory Standards
Institute, 2012) with some modifications. Briefly, all bacterial
strains except K. pneumoniae were cultured in respective media
and grown overnight at 37◦C. Cells were washed with NaPB
buffer, diluted in 10% of Mueller-Hinton (MH) broth (Sigma)
to obtain a concentration of 5 × 106 CFU/mL that were used
as the inoculum. Hst 5 peptide was serially diluted in 10%
MH broth (since it is inactive in undiluted broth) in 96-well
flat-bottomed plates (Falcon). After adding equal volume of
target bacterial suspension to the peptide solution, the 96-well
plates were incubated at 37◦C for 24 h. The MIC values were
determined by visibly recording the lowest concentration of Hst
5 that inhibited growth.
Statistics
Statistical analyses were performed using GraphPad Prism
software version 5.0 (GraphPad Software, San Diego, CA, USA)
using unpaired Student’s t-tests. Differences of P < 0.05 were
considered significant. All experiments were performed at least
thrice.
RESULTS
Hst 5 Has Strong Bactericidal Activity
against Four ESKAPE Pathogens
In order to determine the bactericidal activity of Hst 5 against
ESKAPE pathogens, six clinical isolates (Table 1) were tested
using bactericidal assays (performed in 10 and 100 mM
NaPB buffer) to determine percent bacterial killing following
incubation for 1 min, 1, and 5 h with 30 µM Hst 5. E. faecium
showed time-dependent killing since only 18.1 ± 8.9 percent of
cells were killed by Hst 5 at 1 h, while killing was enhanced to
63.5 ± 3.5 percent after 5 h incubation (Figure 1A). S. aureus
cells incubated for only 1 min with 30 µM Hst 5 showed
28.3 ± 2.3 percent killing which increased to 60.3 ± 5.7 and
69.7 ± 0.2 percent after 1 and 5 h, respectively (Figure 1B). A
MRSA strain of S. aureus had lower but still significant killing
by Hst 5 after 1 h (33.8 ± 3.5%). Interestingly, Hst 5 did not
show any killing activity against K. pneumoniae for up to 5
h of incubation (Figure 1C). A. baumannii AB307-0294 had
substantial sensitivity to Hst 5 with 31.4 ± 3.7, 90.0 ± 1.1,
and 95. ± 2.3 percent killing at 1 min, 1, and 5 h, respectively
(Figure 1D), while the A. baumannii HUMC1 strain had even
higher sensitivity with 100% killing at 1 h. Similarly, Hst 5 also
showed strong killing activity against P. aeruginosa 94-323-0635,
with a faster rate of killing. At just 1 min of incubation, 83.2± 1.3
percent killing was observed; while over 99.9 percent of cells were
killed after 1 h treatment (Figure 1E). P. aeruginosa PAO1 had
identical sensitivity to Hst 5 with 100% of cells killed at 1 h. E.
cloacae sensitivity was similar to that of A. baumannii showing
20.3 ± 1.5, 66.1 ± 0.6, and 78.1 ± 1.7 percent of cells killed by
Hst 5 at 1 min, 1 h, and 5 h, respectively (Figure 1F).
Since the activity of Hst 5 against C. albicans is abolished
at higher phosphate buffer concentrations (Helmerhorst et al.,
1999), Hst 5 killing activity against ESKAPE strains was also
tested in a buffer with higher ionic strength. Killing activities of
Hst 5 against E. faecium, P. aeruginosa, and E. cloacaewere greatly
reduced (Figures 1A,E,F) when carried out in 100 mM NaPB.
However, bactericidal activity against S. aureus at 100 mM NaPB
was similar to that observed in 10 mM NaPB (Figure 1B), while
killing efficiency for A. baumannii were decreased by about 30
percent in 100 mM NaPB after 1 or 5 h incubation (Figure 1D).
Effects of PBS on killing were similar to those seen in 100 mM
NaPB (data not shown).
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FIGURE 1 | Killing of ESKAPE cells by Hst 5. E. faecium (A), S. aureus (B), K. pneumoniae (C), A. baumannii (D), P. aeruginosa (E), and E. cloacae (F) cells in
exponential growth were exposed to 30 µM Hst 5 in 10mM NaPB or 100mM NaPB for 1min, 1, and 5 h. Aliquots taken at different time points were diluted and
plated. CFU were determined after 24 h. Error bars represent the standard errors from at least three independent replicates of each strain.
Based on these bactericidal results, we next tested growth
inhibition by Hst 5 for these ESKAPE pathogens by determining
MIC values in 10%MH broth (since Hst 5 is inactive in undiluted
broth). Hst 5 MIC values of 38, 47, and 90 µMwere observed for
A. baumannii, P. aeruginosa, and E. cloacae; while we could not
determine MIC values for E. faecium and S. aureus due to media
components that inactivate Hst 5 (Table 2).
The activity of Hst 5 against ESKAPE pathogens grown as
biofilms was determined after 16 h growth of each bacteria in
96-well plates (Table 2). Biofilms were treated with 30 µM Hst 5
for 1 h, dead cells stained with PI, and percent killing calculated.
Neither E. faecium or E. cloacae formed robust biofilms in our
hands so that Hst 5 killing could not be reliably determined
for these two pathogens. As for planktonic cells, both strains of
P. aeruginosa in biofilms were effectively killed by Hst 5 after 1 h
(59.5%); however Hst 5 killing of A. baumannii biofilm cells was
reduced to 15.1%; while killing of S. aureus biofilm cells (both
strains) was negligible (5.1%). Surprisingly, we observed that Hst
5 killed 19.5% ofK. pneumoniaewhen in biofilms, although it had
no activity against planktonic cells.
Overall, our results show that Hst 5 has a strong bactericidal
activity against P. aeruginosa and E. cloacae (and weaker killing
with E. faecium) at lower ionic strength environments; while
exerting killing against A. baumannii and S. aureus over a range
of ionic strengths. However, biofilm cells of A. baumannii and
S. aureus were more resistant to Hst 5 killing. To confirm these
findings in real time and to assess whether ionic strength may
influence metabolic or membrane lytic mechanisms of killing, we
next measured Hst 5 binding, uptake, and time of killing for these
ESKAPE pathogens in 10 mM NaPB.
Bactericidal Activity of Hst 5 against
E. faecium and E. cloacae Requires
Internalization and Is Energy Dependent
Time-lapse confocal microscopy showed that Hst 5 (30 µM)
rapidly (<1 min) bound with the surface of E. faecium cells,
although no internalization was evident until after 10 min
of incubation (Figure 2A). This slow internalization resulted
in only 15% of cells taking up F-Hst 5 by 120 min; but in
Frontiers in Cellular and Infection Microbiology | www.frontiersin.org 4 February 2017 | Volume 7 | Article 41
Du et al. Histatin 5 Kills ESKAPE Pathogens
TABLE 2 | Hst 5-mediated killing of ESKAPE pathogens.
% Hst 5 killinga % Hst 5 biofilmKillingb % Hst 5-spd killingc Main mechanism of killing MIC (µM)d
Membrane disruption Energy dependent
Enterococcus faecium 63.6 ND 96.6 - + ND
Staphylococcus aureus 69.8 3.2 69.2 - - ND
Klebsiella pneumoniae 0.0 19.5 0.0 N/A N/A N/A
Acinetobacter baumannii 95.34 15.1 96.8 + - 38
Pseudomonas aeruginosa >99.9 59.5 >99.9 + - 47
Enterobacter cloacae 78.1 ND 90.1 - + 90
aHst 5 (30 µM) killing efficiency of planktonic cells in 10mM NaPB buffer for 5 h.
bHst 5 (30 µM) killing efficiency of biofilm cells in 10mM NaPB buffer for 1 h.
cHst 5-Spd (30 µM) killing efficiency in 10mM NaPB buffer for 5 h.
dMIC in 10% MH broth.
ND, Not Determined; N/A, Not Applicable.
FIGURE 2 | Antibacterial activity of Hst 5 against E. faecium required internalization and is energy dependent. (A) E. faecium cells were exposed to F-Hst 5
(30 µM) and PI (2 µg/mL). F-Hst 5 (green) and PI (red) uptake were measured in parallel by time-lapse confocal microscopy. Images were recorded every 10 min and
selected images of indicated time points were shown. (Scale bar: 5 µm) (B) Quantitative analysis of F-Hst 5 uptake (green line) and PI uptake. Error bars represent the
standard errors from four different fields of image. (C) Cells pretreated with 10mM NaN3 at 37
◦C for 3 h showed decreased susceptibility to Hst 5. (*P < 0.05,
Student’s t-test).
each instance, Hst 5 internalization was accompanied by PI
uptake (indicative of cell death; Figure 2B). This close correlation
between intracellular Hst 5 and PI uptake suggested that targets
of Hst 5 are intracellular rather than its effects being membrane
lytic. However, the percentage of killing from the bactericidal
assay was higher than apparent PI staining, suggesting that some
portion of killing was delayed. To evaluate this, we pretreated
cells with an inhibitor of energy metabolism (NaN3) as a
means to determine whether the killing activity of Hst 5-treated
E. faecium might be dependent upon cell metabolism. As
expected, pretreatment of cells with NaN3 significantly reduced
the killing efficiency of Hst 5 at 1 and 5 h (Figure 2C), showing
that some portion of Hst 5 killing of E. faecium requires target cell
energy, likely for Hst 5 internalization or intracellular organelle
localization.
E. cloacae cells had a very similar response when treated
with F-Hst 5, in that the peptide associated with the surface
of all cells almost immediately, however entry of F-Hst 5 (and
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accompanying PI staining) was slow and only occurred in 20%
of cells within 30 min (Figure 3A). As for E. faecium, there was
a close correlation between intracellular Hst 5 and PI uptake at
all time points (Figure 3B), also pointing toward intracellular
targets for bactericidal activity. E. cloacae cells pretreated with
10 mM NaN3 prior to exposure with 30µM Hst 5 were more
resistant to the killing action of F-Hst 5 (Figure 3C), similar to
the energy dependent mechanism found with E. faecium.
Membrane Disruption Is Involved in
Bactericidal Activity of Hst 5 against
P. aeruginosa and A. baumannii
In agreement with its high bactericidal activity, F-Hst 5
completely covered the cell surface of P. aeruginosa within
1min, and PI positive cells could be visualized within 2min
(Figure 4A). Quantitative analysis showed that 75% of cells
contained F-Hst 5 and were PI positive within 5 min of addition
of F-Hst 5 (Figure 4B). Both intracellular localization of Hst 5
and PI staining were rapid and simultaneous, pointing toward
membrane lytic activity of Hst 5mediated killing of P. aeruginosa.
Pretreatment of P. aeruginosa cells with 10 mM NaN3 did not
reduce the killing activity of Hst 5 (Figure 4C), also suggesting
energy-independent membrane disruption as the main pathway
for Hst 5 killing activity against P. aeruginosa.
A. baumannii showed a very similar profile to P. aeruginosa
after exposure to F-Hst 5 in that F-Hst 5 was associated with
the surface of all cells within 2 min; and PI positive cells were
visualized with 2 min (Figure 5A). Although intracellular uptake
of F-Hst 5 was very rapid with 70% of cells containing F-Hst 5
in just 2 min, PI staining did not occur simultaneously so that
70% PI positive cells was seen only after 25 min (Figure 5B).
Interestingly, the portion of A. baumannii cells that showed
slower PI staining already contained F-Hst 5; so we questioned
whether bactericidal activity of these cells was energy-dependent.
However, NaN3-pretreated A. baumanni cells had no difference
in F-Hst 5 killing (Figure 5C), indicating that Hst 5-mediated
killing of A. baumanni is partially due to membrane lysis and is
energy independent, although some portion of killing might also
be a result of its effect on intracellular targets.
Hst 5-Mediated Killing of S. aureus Is
Delayed and Energy Independent
F-Hst 5 was visualized binding to the cell surface of all S.
aureus cells within 1 min after addition, however intracellular
FIGURE 3 | Antibacterial activity of Hst 5 against E. cloacae requires internalization and is energy dependent. (A) E. cloacae cells were exposed to F-Hst 5
(30 µM) and PI (2 µg/mL). The F-Hst 5 (green) and PI (red) uptake were measured in parallel by time-lapse confocal microscopy. Images were recorded every 10 min
and selected images as indicated time points were shown. (Scale bar: 5 µm) (B) Quantitative analysis of F-Hst 5 uptake (green line) and PI uptake. Error bars
represent the standard errors from four different fields of image. (C) Cells pretreated with 10 mM NaN3 at 37
◦C for 3 h showed more resistance to Hst 5. (***P <
0.001, Student’s t-test).
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FIGURE 4 | Hst 5 bactericidal activity against P. aeruginosa cells is primarily mediated by membrane disruption. (A) P. aeruginosa cells were exposed to
F-Hst 5 (30 µM) and PI (2 µg/mL). F-Hst 5 (green) and PI (red) uptake were measured in parallel by time-lapse confocal microscopy. Images were recorded every 10
min and selected images at indicated time points were shown (Scale bar: 5 µm) (B) Quantitative analysis of F-Hst 5 uptake (green line) and PI uptake. Error bars
represent the standard errors from four different fields of image. (C) Cells pretreated with 10mM NaN3 at 37
◦C for 3 h did not show significant difference in
susceptibility to Hst 5.
FIGURE 5 | Activity of Hst 5 against A. baumannii is mediated in part by membrane disruption. (A) A. baumannii cells in exponential phase were exposed to
F-Hst 5 (30 µM) and PI (2 µg/mL). The F-Hst 5 (green) and PI (red) uptake were measured in parallel by time-lapse confocal microscopy. Images were recorded every
2 min and selected images as indicated time points were shown. (Arrow, cells of F-Hst 5 uptake positive but without PI uptake; Scale bar: 5 µm). (B) Quantitative
analysis of F-Hst 5 uptake (green line) and PI uptake. Error bars represent the standard errors from four different fields of image. (C) Cells pretreated with 10 mM NaN3
at 37◦C for 3 h did not show significant difference in susceptibility to Hst 5.
Frontiers in Cellular and Infection Microbiology | www.frontiersin.org 7 February 2017 | Volume 7 | Article 41
Du et al. Histatin 5 Kills ESKAPE Pathogens
FIGURE 6 | The activity of Hst 5 against S. aureus is mediated by energy-independent mechanisms. (A) S. aureus cells were exposed to F-Hst 5 (30 µM)
and PI (2 µg/mL). F-Hst 5 (green) and PI (red) uptake were measured in parallel by time-lapse confocal microscopy. Images were recorded every 10 min and selected
images of indicated time points were shown. (Scale bar: 5 µm). (B) Quantitative analysis of F-Hst 5 uptake (green line) and PI uptake. Error bars represent the
standard errors from four different fields of image. (C) Cells pretreated with 10mM NaN3 at 37
◦C for 3 h did not show significant difference in susceptibility to Hst 5.
localization and PI uptake occurred slowly (Figure 6A), so that
by 120 min only 7% of cells contained F-Hst 5 and were
PI positive (Figure 6B). This was surprising since bactericidal
activity of Hst 5 after 1 h incubation was found to have 60%
killing (Figure 1). Furthermore, bactericidal assay with S. aureus
pretreated with 10 mM NaN3 did not decrease the killing
efficiency (Figure 6C). These results, combined with the salt-
insensitive killing, suggest that there may be multiple targets for
Hst 5-mediated killing of S. aureus that are non-lytic and energy
independent.
Hst 5 Is Ineffective in Killing K. Pneumoniae
due to Lack of Sustained Binding
Since Hst 5 showed negligible killing against K. pneumoniae
(Figure 1C), we examined the reason for this using confocal
microscopy. F-Hst bound to most K. pneumoniae cells within
2 min, however by 10 min most binding was lost suggesting
detachment of Hst 5 from the surface capsule (Figure 7A).
As expected, F-Hst 5 and PI uptake were extremely limited
(only 2% of cells), even up to 150 min (Figure 7B). These
results suggest that F-Hst 5 is released from the K. pneumoniae
after initial binding (perhaps due to lower binding efficacy
in the presence of its capsule) and thus Hst 5 is unable to
gain entry or lyse the cells and therefore is ineffective against
K. pneumoniae.
Hst 5-Spd Has Improved Bactericidal
Efficiency against ESKAPE Pathogens That
Take Up Hst 5
We have previously reported that spermidine-conjugated Hst 5
(Hst 5-Spd) has greater activity against C. albicans because the
spermidine conjugate translocates more efficiently into the yeast
cells (Tati et al., 2014). Therefore, to determine if Hst 5-Spd
has improved bactericidal activity against ESKAPE pathogens
as well, we tested the killing activity of Hst 5-Spd [30 µM]
against all the six strains (Figure 8). Interestingly, Hst 5-Spd
had significantly higher killing activity compared with Hst 5
against E. faecium, E. cloacae, and A. baumannii (Figure 8). Hst
5-Spd bactericidal effects were most improved against E. faecium;
increased by three-fold after 1 h incubation and by 1.5-fold after
5 h, while Spermidine (Spd) alone had no killing activity even
after 5 h treatment (Figure 8A). Hst 5-Spd bactericidal activity
was also increased significantly in E. cloacae compared with Hst
5, although by only 15% at 1 h and at 5 h. Hst 5-Spd also showed
a small but significant increase in killing activity against A.
baumannii compared with Hst 5 (23% at 1 min and 10% at 1 h).
However, after 5 h there was no significant difference perhaps due
to the high killing that occurred as a result of Spd (30 µM) itself
(Figure 8D). These three species of ESKAPE pathogens were also
ones that we found to involve Hst 5 uptake and intracellular
targets (Figures 2, 3, 5), suggesting that improved Hst 5-Spd
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FIGURE 7 | Hst 5 is minimally active against K. pneumoniae. (A) K.
pneumoniae cells in exponential phase were exposed to F-Hst 5 (30 µM) and
PI (2 µg/mL). F-Hst 5 (green) and PI (red) uptake were measured in parallel by
time-lapse confocal microscopy. Images were recorded every 10min and
selected images of indicated time points were shown. (Scale bar: 5 µm). (B)
Quantitative analysis of F-Hst 5 uptake (green line) and PI uptake. Error bars
represent the standard errors from four different fields of image.
activity in these strains is a result of improved uptake. This is
supported by our data showing that the killing ability of Hst
5-Spd against P. aeruginosawas not improved, in agreement with
amembrane lytic mechanism for this organism. Furthermore, the
Hst 5 resistant pathogen K. pneumoniae was not affected by Hst
5-Spd showing that this conjugate does not improve binding to
this encapsulated ESKAPE pathogen.
DISCUSSION
Here we report the remarkable finding that although Hst 5
activity has been believed to be limited to fungi, Hst 5 also
demonstrates very high bactericidal activity against several
ESKAPE pathogens. Up to now, a few reports have described
interactions between Hst 5 and bacteria. Hst 5 was found
to have low killing against Streptococcus gordonii (a Gram-
positive commensal bacterium of the human oral cavity; Andrian
et al., 2012). Zinc-mediated killing of E. faecalis bacteria by
histidine–rich histatin analogs was found (Rydengard et al.,
2006), and killing activity of another histatin derivative (P113)
against P. aeruginosa and S. aureus in vitro was shown
(Giacometti et al., 2005). Hst 5 may have other non-bactericidal
activities in that it attenuates chemokine responses by binding
to Porphyromonas gingivalis hemagglutinin B (Borgwardt et al.,
2014). Here we expand the scope of Hst 5 activity by showing
that full length Hst 5 and an Hst 5 spermidine conjugate both
exert very significant killing of all but one ESKAPE pathogen by
multiple mechanisms.
Themechanisms by whichHst 5, a naturally occurring salivary
protein, kills C. albicans have been well-studied and suggest the
involvement of multiple intracellular targets (Puri and Edgerton,
2014). The effects on fungal targets range from non-lytic leakage
of ATP and K+ ions to mitochondrial damage and oxidative
stress generation (Puri and Edgerton, 2014); and more recently,
potential metal scavenging causing nutritional stress (Puri et al.,
2015). However, it has been clearly shown that the killing is
non-lytic and energy dependent. Interestingly, the ambiguity in
the mechanisms of antimicrobial peptides seems universal. Many
antibacterial peptides that were considered to be purely lytic are
now believed to involve other killing mechanisms ranging from
bacterial cell wall disruption to effects on protein and nucleic acid
synthesis (Brogden, 2005). We found that Hst 5 can efficiently
kill ESKAPE pathogens killing using a unique blend of lysis and
energy dependency.
Antibiotic resistance has been a challenge for treating drug
resistant bacterial infections and ESKAPE pathogens are no
exception (Rice, 2010). One classic drug resistance mechanism
entails eﬄux of the antimicrobial molecules by bacterial cells
(Sun et al., 2014). However, Hst 5 resistance is mediated by eﬄux
through C. albicans Flu1 transporters (Li et al., 2013) and is not
likely to occur in bacteria, as there are no similar transporters
known in bacteria. In contrast, C. albicans Dur3 transporters
(used in polyamine uptake in fungi) are needed for Hst 5 uptake
and candidacidal activity (Kumar et al., 2011). Interestingly
all ESKAPE pathogens have spermidine/polyamine transporter
homologs (Palmer et al., 2010; Ren et al., 2010; Park et al., 2011;
Liu et al., 2012; Yao and Lu, 2014; Wang et al., 2016) that might
mediate Hst 5 uptake in pathogens that require internalization
for killing. Also, the improved bactericidal activity of the Hst
5-spermidine conjugate against E. faecium (whose spermidine
transporter has the highest homology to the C. albicans Dur3
transporter, our unpublished data), and to some extent against
E. cloacae and A. baumannii may be a result of better uptake
due to similarity of polyamine transporters expressed in these
cells. Biofilm formation is another resistance mechanism that
leads to poor drug penetration and accessibility (del Pozo and
Patel, 2007; Hoiby et al., 2010). It has previously been shown
that Hst 5 is effective against C. albicans biofilm (Konopka et al.,
2010) and thus Hst 5 can potentially make its way through the
polysaccharide extracellular biofilm matrix of ESKAPE bacteria
as well.
Prophylactic antimicrobial therapy, especially when applied
topically, can be of great advantage to prevent surgical, wound,
and burn infections. However, depending on the specificity of
the agent used, this may also lead to the killing of healthy
flora at the site of application that prevents colonization of
pathogens. Here we show that salivary Hst 5 that has limited
antibacterial activity against most human oral commensal
organisms including Streptococcal sp. (found on the human skin;
Dale and Fredericks, 2005; Belkaid and Segre, 2014), is extremely
effective against P. aeruginosa and A. baumanni. This provides
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FIGURE 8 | Killing of ESKAPE pathogens by Hst 5-Spd. E. faecium (A), S. aureus (B), K. pneumoniae (C), A. baumannii (D), P. aeruginosa (E), and E. cloacae (F)
cells in exponential growth were exposed to 30 µM of Hst 5, F-Hst 5 and spermidine in 10 mM NaPB for 1 min, 1, and 5 h. Aliquots taken at different time points were
diluted and plated. CFU were determined after 24 h. Error bars represent the standard errors from at least three independent replicates of each strain. Hst 5-Spd
conjugate showed more killing efficiency against E. faecium (A), A. baumannii (D), and E. cloacae (F) (**P < 0.01, ***P < 0.001, Student’s t-test).
a novel potential therapeutic application for Hst 5 since P.
aeruginosa is one of the most important causative agents for burn
infections (Tredget et al., 1992). Furthermore, P. aeruginosa is
responsible for a majority of bacterial eye infections related to
contact lens use (Cope et al., 2016). While Hst 5 is intrinsically
absent from human tears, its exogenous application to treat such
infections seems plausible, given the high killing activity of Hst
5 against P. aeruginosa. Potential therapeutic use of Hst 5 has
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some limitations that are inherent to its cationic nature. Since
high salt conditions negatively affect Hst 5 microbicidal activity
(Helmerhorst et al., 1999; Jang et al., 2010), this may restrict the
use of Hst 5 for treatment of systemic disease, although the Hst 5
derivative P113 was found to be effective for systemic use in a rat
model of P. aeruginosa sepsis (Cirioni et al., 2004). However Hst
5 has a great potential for application topically, both on human
skin and in the eye, especially when carried in hypotonic gels and
solutions.
Multiple drugs are sometimes required to completely
eradicate drug resistant infections. Although further testing of
additional strains of ESKAPE pathogens needs to be done, we
show here the killing activity of Hst 5 against ESKAPE pathogens,
taken together with how Hst 5 can potentially affects multiple
intracellular targets, presents the possibility of using this protein
in synergy with other existing antibiotics.
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